Cargando…
Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
BACKGROUND: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for who...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404930/ https://www.ncbi.nlm.nih.gov/pubmed/22613958 http://dx.doi.org/10.1186/1471-2407-12-185 |
_version_ | 1782239044595351552 |
---|---|
author | Fujita, Shiro Katakami, Nobuyuki Masago, Katsuhiro Yoshioka, Hiroshige Tomii, Keisuke Kaneda, Toshihiko Hirabayashi, Masataka Kunimasa, Kei Morizane, Toshio Mio, Tadashi |
author_facet | Fujita, Shiro Katakami, Nobuyuki Masago, Katsuhiro Yoshioka, Hiroshige Tomii, Keisuke Kaneda, Toshihiko Hirabayashi, Masataka Kunimasa, Kei Morizane, Toshio Mio, Tadashi |
author_sort | Fujita, Shiro |
collection | PubMed |
description | BACKGROUND: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized based on EGFR mutation status. METHODS: We screened 57 chemotherapy-naïve patients with histologically or cytologically confirmed NSCLC, stage IIIB or IV, aged 70 years or older, and with an Eastern Cooperative Oncology Group performance status 0 or 1, for EGFR exon 19 codon 746–750 deletion and exon 21 L858R mutation. Twenty-two patients with EGFR mutations received gefitinib; 32 patients without mutations received vinorelbine or gemcitabine. The primary endpoint was the response rate. RESULTS: The response rate was 45.5% (95% confidence interval [CI]: 24.4%, 67.8%) in patients with EGFR mutations and 18.8% (95% CI: 7.2%, 36.4%) in patients without EGFR mutations. The median overall survival was 27.9 months (95%CI: 24.4 months, undeterminable months) in patients with EGFR mutations and 14.9 months (95%CI: 11.0 months, 22.4 months) in patients without EGFR mutations. In the gefitinib group, grade 3/4 hepatic dysfunction and dermatitis occurred in 23% and 5% of patients, respectively. In patients treated with vinorelbine or gemcitabine, the most common grade 3 or 4 adverse events were neutropenia (47%; four had febrile neutropenia), anemia (13%), and anorexia (9%). No treatment-related deaths occurred. CONCLUSIONS: Treatment customization based on EGFR mutation status deserves consideration, particularly for elderly patients who often cannot receive second-line chemotherapy due to poor organ function or comorbidities. TRIAL REGISTRATION: This trial is registered at University hospital Medical Information Network-clinical trial registration (http://www.umin.ac.jp/ctr/index/htm) with the registration identification number C000000436. |
format | Online Article Text |
id | pubmed-3404930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34049302012-07-26 Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial Fujita, Shiro Katakami, Nobuyuki Masago, Katsuhiro Yoshioka, Hiroshige Tomii, Keisuke Kaneda, Toshihiko Hirabayashi, Masataka Kunimasa, Kei Morizane, Toshio Mio, Tadashi BMC Cancer Research Article BACKGROUND: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized based on EGFR mutation status. METHODS: We screened 57 chemotherapy-naïve patients with histologically or cytologically confirmed NSCLC, stage IIIB or IV, aged 70 years or older, and with an Eastern Cooperative Oncology Group performance status 0 or 1, for EGFR exon 19 codon 746–750 deletion and exon 21 L858R mutation. Twenty-two patients with EGFR mutations received gefitinib; 32 patients without mutations received vinorelbine or gemcitabine. The primary endpoint was the response rate. RESULTS: The response rate was 45.5% (95% confidence interval [CI]: 24.4%, 67.8%) in patients with EGFR mutations and 18.8% (95% CI: 7.2%, 36.4%) in patients without EGFR mutations. The median overall survival was 27.9 months (95%CI: 24.4 months, undeterminable months) in patients with EGFR mutations and 14.9 months (95%CI: 11.0 months, 22.4 months) in patients without EGFR mutations. In the gefitinib group, grade 3/4 hepatic dysfunction and dermatitis occurred in 23% and 5% of patients, respectively. In patients treated with vinorelbine or gemcitabine, the most common grade 3 or 4 adverse events were neutropenia (47%; four had febrile neutropenia), anemia (13%), and anorexia (9%). No treatment-related deaths occurred. CONCLUSIONS: Treatment customization based on EGFR mutation status deserves consideration, particularly for elderly patients who often cannot receive second-line chemotherapy due to poor organ function or comorbidities. TRIAL REGISTRATION: This trial is registered at University hospital Medical Information Network-clinical trial registration (http://www.umin.ac.jp/ctr/index/htm) with the registration identification number C000000436. BioMed Central 2012-05-21 /pmc/articles/PMC3404930/ /pubmed/22613958 http://dx.doi.org/10.1186/1471-2407-12-185 Text en Copyright ©2012 Fujita et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Fujita, Shiro Katakami, Nobuyuki Masago, Katsuhiro Yoshioka, Hiroshige Tomii, Keisuke Kaneda, Toshihiko Hirabayashi, Masataka Kunimasa, Kei Morizane, Toshio Mio, Tadashi Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial |
title | Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial |
title_full | Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial |
title_fullStr | Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial |
title_full_unstemmed | Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial |
title_short | Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial |
title_sort | customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase ii trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404930/ https://www.ncbi.nlm.nih.gov/pubmed/22613958 http://dx.doi.org/10.1186/1471-2407-12-185 |
work_keys_str_mv | AT fujitashiro customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT katakaminobuyuki customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT masagokatsuhiro customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT yoshiokahiroshige customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT tomiikeisuke customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT kanedatoshihiko customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT hirabayashimasataka customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT kunimasakei customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT morizanetoshio customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial AT miotadashi customizedchemotherapybasedonepidermalgrowthfactorreceptormutationstatusforelderlypatientswithadvancednonsmallcelllungcanceraphaseiitrial |